Sirtex Medical chief executive Andrew McLean is confident the $1.9 billion takeover deal penned with China's CDH Investments will not hit any regulatory hurdles in the US despite the ramped-up power of agencies under President Donald Trump's America First campaign.

Clinching the deal would be a win for patient shareholders, who have watched Sirtex hit a peak market value of $2.3 billion in December 2015 before it tumbled to just $800 million on concerns about the efficacy of its innovative radioactive devices used to treat liver cancer. Prior to the Varian bid in January, the company was valued at about $1 billion.